Latest fiscal year 2025 · computed deterministically from XBRL 10-K data · coverage 100%
In fiscal 2025, TransMedics Group, Inc. reported revenue of $605M, up 37.1% year over year. Operating margin was 17.9% and net margin 31.4%, on a free-cash-flow margin of 22.1% with capital expenditure at 9.8% of revenue. Every figure is computed directly from TMDX's SEC XBRL 10-K filing — deterministic, with no estimates.
| Fiscal year | Revenue | Op margin | Net margin |
|---|---|---|---|
| FY2025 | $605M | 17.9% | 31.4% |
| FY2024 | $442M | 8.5% | 8.0% |
| FY2023 | $242M | -11.9% | -10.4% |
| FY2022 | $93M | -33.6% | -38.8% |
| FY2021 | $31M | -125.6% | -140.9% |
How does TMDX compare against its actual peer set?
A CompsDesk subscription covers unlimited benchmark packs on any covered company: up to 19 metrics (6 core guaranteed) × up to 5 fiscal years × up to 12 chosen peers, percentile placement, the subject's figures cited to their SEC tag, form and period with every company identified by its CIK, PDF-ready HTML + CSV, generated on demand.
Related in the same sector: A · ACHR · AEHR · AERG · AEVA · AIRI
Source: SEC EDGAR XBRL (10-K filings), latest filed values. "n/a" = not disclosed under mapped tags — never estimated. Informational benchmarking, not investment advice. © CompsDesk / Sam Arora.